

Program

IPNC2025

**24th International Pathogenic
Neisseria Conference**

Palazzo dei Congressi
Piazza Adua, 1 - Florence (Italy)

www.ipnc2025.com

30 MARCH
4 APRIL



30/03/2025

17:30-18:30

Auditorium

Opening Lecture

Chair: C. AZZARI (*ITALY*)

Vaccine technologies

R. RAPPUOLI

Fondazione Biotechnopolo di Siena, Siena (ITALY)

18.30-20.00 Welcome Reception

Program

30 MARCH

31/03/2025

09:00-15:15

Auditorium

Neisseriae: Clinical relevance and epidemiology in 2025

Chair: D. CAUGANT (*NORWAY*), N. E. BASTA (*CANADA*)

- 09:00-09:30 Keynote Lecture**
Evolution of the pathogenic Neisseria: links to clinical presentations and pathogenesis
D. STEPHENS
Emory University School of Medicine, Atlanta (USA)
- 09:30-09:50 A manually curated pathway and genome database for Neisseria Gonorrhoeae FA 1090**
B. WILSON-MORTIER
Macquarie University, Department of Natural Sciences, Sydney (AUSTRALIA)
- 09:50-10:10 LIN code: a robust approach for defining and exploring gonococcal lineages**
A. UNITT
NDPH, University of Oxford, Oxford (UNITED KINGDOM)
- 10.10-11.10 Coffee Break**
- 11:20-11:40 A large outbreak of Neisseria meningitidis serogroup C and the first global use of Men5CV – Nigeria, October 2023 – June 2024**
A.L. MOHAMMED
Nigeria Centre for Disease Control and Prevention, Abuja (NIGERIA)

Program

31 MARCH

Flash Poster Presentations

Chairs: S. JACOBSSON (SWEDEN), C. VIPOND (UNITED KINGDOM)

- 11:40-11:45 High Neisseria meningitidis oropharyngeal carriage trends in men who have sex with men: a public health warning**
A. MEMON
University of Oxford, Nuffield Department of Population Health, Oxford (UNITED KINGDOM)
- 11:45-11:50 Update on the epidemiology of invasive meningococcal disease: Canada 2002-2023**
J. BETTINGER
Vaccine Evaluation Center British Columbia Childrens Hospital Research Institute UBC, Vancouver (CANADA)
- 11:50-11:55 Assessing maternal contributions to the prevention and control of sporadic meningitis in rural communities: a growing concern of geographic risk dynamics and migration from high-burden regions**
C.A. IWU
Imo State University/Teaching Hospital, Owerri (NIGERIA)
- 11:55-12:00 Assessing the use of point of care diagnostic testing for invasive meningococcal disease and the impact of this on the implementation of essential public health actions**
E. HEYMER
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, Colindale, London (UNITED KINGDOM)
- 12:00-12:05 Turbo, an adjuvant for multivalent meningococcal glycoconjugate vaccines**
K. ALUGUPALLI
TurboVax Inc, Philadelphia (USA)
- 12:05-12:10 Insights into the epitope-specific roles of Neisseria gonorrhoeae reduction modifiable protein (Rmp) in modulating bactericidal activity**
V. KASIMOV (1,2)
Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD (AUSTRALIA), Gold Coast Sexual Health Clinic, Southport Community Health Precinct, Southport, QLD (AUSTRALIA)
- 12:10-12:15 A combination native outer membrane vesicle (NOMV) vaccine to prevent meningococcal and gonococcal disease**
S. GIUNTINI
OMVAX INC., OAKLAND, CALIFORNIA (USA)
- 12:15-12:20 The importance of selecting outer membrane antigens from Neisseria meningitidis strains associated with different meningococcal polysaccharides for an effective protection**
N. SIMOES DE MELO
Adolfo Lutz Institute, Immunology Center, São Paulo (BRAZIL)

Program

31 MARCH

- 12:25-12:30** **Estimating the impact of immunization against Neisseria meningitides with a pentavalent conjugate vaccine compared to monovalent serogroup A conjugate vaccine in the African meningitis belt**
A. HABIB
Bayero University Kano, Kano (NIGERIA)
- 12:30-12:35** **Identification and control of an outbreak of serogroup Y invasive meningococcal disease in Quebec**
P.D.W. DE WALS
Laval University, Québec (CANADA)
- 12:35-12:40** **Extracellular vesicles carrying complement inhibitors enhance Neisseria gonorrhoeae serum resistance**
N. WEYAND
Ohio University, Athens (USA)
- 12.40-14.15** **Lunch break**

Chairs: C. BAYLISS (*UNITED KINGDOM*), B. BØRUD (*NORWAY*)
- 14:15-14:35** **Genomic analysis uncovers multiple strains in Umrah- and travel-related outbreak of serogroup W invasive meningococcal disease ahead of Hajj 2024**
J. LUCIDARME
UK Health Security Agency - Meningococcal Reference Unit, Manchester (UNITED KINGDOM)
- 14:35-14:55** **Fluctuations in serogroup B meningococcal vaccine antigens prior to routine MenB vaccination in France**
A.-E. DEGDMANE
Institut Pasteur, Paris (FRANCE)

Program

31 MARCH

Testimonies of life after disease

Chairs: C. AZZARI (*ITALY*), F. MARTINON TORRES (*SPAIN*)

- 15:00-15:30** **Talk: Gonorrhea in LMIC and impacts on women and children**
S. DELANY-MORETLWE
Wits RHI, University of the Witwatersrand, Johannesburg (SOUTH AFRICA)
- 15:30-16:00** **Advocates driving change to defeat meningitis**
V. SMITH
Meningitis Research Foundation (UNITED KINGDOM)
- 16:00-16.45** **Coffee Break**
- 16:45-18:00** **Poster session: Poster viewing**

Program

31 MARCH

01/04/2025

09:00-14:00

Auditorium

Meningococcal and gonococcal vaccines

Chairs: J. DERRICK (*UNITED KINGDOM*), G. POLLOCK (*AUSTRALIA*)

- 09:00-09:30 Keynote Lecture**
Gonorrhoea vaccines: status and challenges in 2025
A. JERSE
Uniformed Services University of the Health Sciences, Bethesda (USA)
- 09:30-10:00 Keynote lecture**
Meningococcal Vaccines: Where We Are and Where We're Headed
F. MARTINON TORRES
Hospital Clínico Universitario, Santiago de Compostela (SPAIN)
- 10:00-10:20 Long-term protection against invasive meningococcal disease and gonorrhoea, 5 years after implementation of an infant and adolescent 4CMenB vaccine program in South Australia**
H. MARSHALL
Women's and Children's Health Network and The University of Adelaide, Adelaide (AUSTRALIA)
- 10:20-10:40 Impact of 4CMenB and MenB-fHbp on pharyngeal carriage in UK adolescents: The 'Be on the TEAM' randomised controlled trial**
J. CARR
University of Oxford, Oxford (UNITED KINGDOM)
- 10.40-11.20 Coffee Break**

Chairs: K.SEIB (*AUSTRALIA*), P. T. BEERNINK (*USA*)
- 11:20-11:40 Immunogenicity and functionality of a N. gonorrhoeae vaccine (LTB-NG6) in animals**
P. CARRANZA
LimmaTech Biologics AG, Schlieren (SWITZERLAND)
- 11:40-12:00 Mucosal and serum immune responses against Neisseria gonorrhoeae (Ng) outer membrane vesicle antigens following meningococcal 4CMenB immunization in healthy adults**
V. PHADKE
Hope Clinic of Emory University, Atlanta (USA)
- 12:00-12:20 Characterising the genetic diversity of the Neisseria gonorrhoeae outer-membrane protein PorB for improved vaccine development and surveillance**
O. HARRISON
University of Oxford, Nuffield Department of Population Health, Oxford (UNITED KINGDOM)
- 12:20-12:40 Expression of gonococcal 2C7 lipopolysaccharide on meningococcal outer membrane vesicles**
P.V.D.L. VAN DER LEY
Intravacc, Bilthoven (THE NETHERLANDS)

Program

1 APRIL

Lunch Roundtable I - Defeating meningitis by 2030: a global roadmap

Chairs: Ziad Memish (SAUDI ARABIA), Mariagrazia Pizza (UNITED KINGDOM)

- 12:50-12:55 Introduction**
Ziad Memish (SAUDI ARABIA), Mariagrazia Pizza (UNITED KINGDOM)
- 12:55-13:10 The WHO global roadmap: we will defeat meningitis by 2030**
-The WHO roadmap and progress updates since last IPNC
-The business case for defeating meningitis
-The five pillars of the roadmap
-Pillar I: prevention and epidemic control: new vaccines will meet the roadmap's goal to eliminate bacterial meningitis epidemics
Marie-Pierre Preziosi
World Health Organization, Geneva (SWITZERLAND)
- 13:10-13:20 Global epidemiology of N. meningitidis**
Caroline Trotter
University of Cambridge (UNITED KINGDOM)
- 13:20-13:30 Global landscape of meningococcal vaccine use policies and practice**
Nicole Basta
Mcgill University, Montréal-Québec (CANADA)
- Regional and national implementation plans for defeating meningitis**
- 13:30-13:40 The Eastern Mediterranean regional implementation plan**
Messeret Eshetu Shibeshi
WHO Eastern Mediterranean Regional Office (EGYPT)
- 13:40-13:50 The Brazil national plan**
Caroline Gava Alves
Ministry of Health (BRAZIL)
- 13:50-14:00 Q&A**

Program

1 APRIL

GSK Symposium: Evolution of Neisseria meningitidis serogroup B strain coverage methods: the prospects of harnessing machine learning technology to further improve strain coverage predictions

- 14:00-14:05** **Opening remarks**
M.-K. TAHA
Institut Pasteur, Paris (FRANCE)
- 14:05-14:20** **Classic principal laboratory methods**
J. LUCIDARME
UK Health Security Agency, Manchester-Greater Manchester (UNITED KINGDOM)
- 14:20-14:35** **Estimation of strain coverage with different methods and how it compares to RWE**
M.-K. TAHA
Institut Pasteur, Paris (FRANCE)
- 14:35-14:50** **GeCoPred - Machine learning in strain coverage prediction**
M. BODINI
GSK, Siena (ITALY)
- 14:50-15:00** **Closing Remarks, Q&A, Discussion**
M.-K. TAHA
Institut Pasteur, Paris (FRANCE)

Program

1 APRIL

Serum Institute of India Symposium: Can Men5CV the novel pen-tavalent meningococcal conjugate vaccine play a key part in “Defeating Meningitis by 2030 - Global road map”

- 15:00-15:10** **Welcome: Can Men5CV Help Defeat Meningitis by 2030?**
S. BERKLEY
Serum Institute of India Pvt Ltd, Pune (INDIA)
- 15:10-15:20** **Advances in vaccine technology and the development of MenFive®**
P. KULKARNI
Serum Institute of India Pvt Ltd, Pune (INDIA)
- 15:20-15:30** **Perspectives from MenAfriVac and Men5CV clinical trials; how research can shape vaccine policy and uptake**
M. TAPIA
Centre for Vaccine Development, University of Maryland, (USA)
- 15:30-15:40** **Turning evidence into policy: WHO SAGE recommendations and Men5CV’s role in defeating meningitis by 2030**
A. HABIB
Bayero University, Kano (NIGERIA)
- 15:40-16:00** **Moderated Panel Discussion + Audience Q&A**
Moderator: S. BERKLEY
Serum Institute of India Pvt Ltd, Pune (INDIA)
- 16.00-16.30** **Coffee Break**

Program

1 APRIL

16:30-18:00

**Policy regulation/ Cost-effectiveness
Roundtable II - Defeating Meningitis in the African
Meningitis Belt**

Chair: Marie-Pierre Preziosi (SWITZERLAND)

- 16:30–16:42** **Epidemiology of N. meningitidis in the African Meningitis Belt**
Caroline Trotter
University of Cambridge (UNITED KINGDOM)
- 16:42–16:54** **Use of new MMCVs to put African countries on the path to elimination of epidemics**
Abdulrazaq Habib
Bayero University, Kano (NIGERIA)
- 16:54–17:06** **Gavi's Vaccine Support Programmes: MMCVs in the Gavi Vaccine Investment Strategy**
Marta Tufet
Gavi, the Vaccine Alliance, Geneva (SWITZERLAND)
- 17:06–17:18** **Assessing impact of MMCVs use strategies- Need for Continued Surveillance and Carriage Studies**
Dominique Caugant
Norwegian Institute Of Public Health, Oslo (NORWAY)
- 17:18–17:30** **Policy Considerations for the Use of MMCVs in the African meningitis belt and globally**
Ziad Memish
King Saud medical city, Riyadh (SAUDI ARABIA)
- 17:30–18:00** **Fireside Chat: Looking Ahead: Renewing the Research Agenda in the Context of New MMCVs – Q&A**

Program

1 APRIL

02/04/2025

09:00-18:00

Auditorium

Clinical studies and translational research and correlates of protection

Chairs: R. READ (*UNITED KINGDOM*), A. SCHUBERT-UNKMEIR (*GERMANY*)

- 09:00-09:30** **Keynote Lecture**
Controlled Human Infection with *N. gonorrhoeae*, role of this model in understanding pathogenesis and immunity
J.A. DUNCAN
University of North Carolina School of Medicine, Chapel Hill (USA)
- 09:30-09:50** **A randomised controlled trial of 4CMenB vaccine against gonorrhoea incidence**
C.C.M. THNG
Gold Coast Sexual Health Service, Gold Coast University Hospital, Gold Coast (AUSTRALIA),
- 09:50-10:50** **Coffee Break**
- 10:50-11:10** **ANRS 174 DOXYVAC: a randomized trial to prevent STI in MSM using antibiotic prophylaxis or 4CMENB vaccine**
M. MOLINA
University of Paris School of Medicine, Paris (FRANCE)
- 11:10-11:30** **Ability of MENB-FHBP-containing vaccines to provide immune protection against serogroup B sequence TYPE 1161 UK University outbreak strains**
J. FINDLOW
Vaccines/Antivirals and Evidence Generation, Pfizer Ltd, Tadworth (UNITED KINGDOM)

Program

2 APRIL

Flash Poster Presentations

Chairs: M. P. MAHLANGU (*SOUTH AFRICA*), A. UNITT (*UNITED KINGDOM*)

- 11:30-11:35** **A Bioluminescence-based high-throughput Serum Bactericidal Assay to detect bactericidal antibodies against *N. meningitis* in human sera**
G. FANTONI
University of Siena, Siena (ITALY)
- 11:35-11:40** **Evaluation of the impact of insecurity and the COVID-19 pandemic on meningitis surveillance in Burkina Faso, 2015–2021**
A.-G. SAWADOGO
Jhpiego Corporation, Ouagadougou (BURKINA FASO)
- 11:40-11:45** **Two decades of *Neisseria gonorrhoeae* evolution in Western Kenya**
O. HARRISON
University of Oxford, Nuffield Department of Population health, Oxford (UNITED KINGDOM)
- 11:45-11:50** **Clinical management of gonorrhoea contacts: evaluation of a change from universal to selective treatment**
E. CHOW
Melbourne Sexual Health Centre, Alfred Health, Melbourne (AUSTRALIA)
- 11:55-12:00** **Female sex hormones enhance gonococcal colonization at the endocervix by modifying cervical mucus**
W. SONG
University of Maryland, College Park - Department of Cell Biology and Molecular Genetics, College Park (USA)
- 12:00-12:05** **Neutrophil-Derived catecholamines support gonococcal resistance to nutritional immunity**
C. WESTLAKE
University of Virginia - Department of Microbiology, Immunology, and Cancer Biology, Charlottesville (USA)
- 12:05-12:10** **Initiation of Gonococcal Pilus Assembly by PilC: the licensing model**
A. MERZ
University of Washington, Seattle (USA)
- 12:10-12:15** **Macrophage infectivity potentiators are important in pathogenic *Neisseria* spp. for host innate defences and antibiotic resistance.**
T.J. HOOTON
University of Western Australia - Marshall Centre for Infectious Disease Research and Training, Perth (AUSTRALIA)
- 12:15-12:20** **Evolution and phylogeny of the newly characterized ssn protein family of site-specific single-stranded DNA endonucleases in *Neisseriae* and beyond**
F. VERYRIER
Armand-Frappier Santé Biotechnologie Research Centre, INRS, Laval (CANADA)

Program

2 APRIL

- 12:20-12:25** **Impact of the L421P mutation in the ponA1 gene, encoding Penicillin-Binding Protein 1, on fitness and antibiotic resistance in Neisseria gonorrhoeae**
R. NICHOLAS
University of North Carolina at Chapel Hill, Chapel Hill (USA)
- 12:25-12:30** **The central role of the beta3-beta4 loop of penicillin-binding protein 2 in the cephalosporin resistance of N. gonorrhoeae**
C. DAVIES
University of South Alabama, Mobile (USA)
- 12:30-12:35** **Accelerated antimicrobial resistance testing of Neisseria gonorrhoeae in sexual health samples**
A. DHANJAL
School of Clinical Dentistry, University of Sheffield, Sheffield (UNITED KINGDOM)
- 12.40-14.00** **Lunch Break**

Chairs: E. CHOW (AUSTRALIA), K. POLYAC (USA)
- 14:00-14:20** **A potent monoclonal antibody against gonococcal lipooligosaccharide with enhanced effector function and plasma half-life**
D. GILL
StiRx Inc, Cambridge (USA)
- 14:20-14:40** **Human monoclonal antibodies targeting subdominant meningococcal antigens reveal cross-protection against gonococcus**
E. ANDREANO
Fondazione Toscana Life Sciences, Siena (ITALY)
- 14:40-15:00** **Strain selection for the development of an oropharyngeal gonorrhoea controlled human infection model**
G. POLLOCK
The University of Melbourne - Department of Infectious Diseases, Melbourne (AUSTRALIA)
- 15:00-15:20** **Unctional impact of novel properdin variants in patients with invasive meningococcal disease**
A. DURET
Department of Paediatric Infectious Diseases, St Mary's Hospital, Imperial College, London (UNITED KINGDOM)
- 15.20-16.00** **Coffee Break**

Program

2 APRIL

16:00-17:00 Round table on Preventing Gonococcal Infection Utilizing the 4CMenB Vaccine

Chairs: C. DEAL (*USA*), S. LADHANI (*UNITED KINGDOM*)

Speakers:

H. MARSHALL

University of Adelaide (AUSTRALIA)

K. SEIB

Institute for Biomedicine and Glycomics, Gold Coast, (AUSTRALIA)

P. WHITE

Modelling & Economics Unit, UK Health Security Agency, London (UNITED KINGDOM)

17:00-18:00 Poster session: poster viewing

Program

2 APRIL

03/04/2025

09:00-12:35

Auditorium

Bacterial physiology and virulence, and in vivo & in vitro models

Chairs: A. CRISS (USA), E. BILLE (FRANCE)

- 09:00-09:30 Keynote Lecture**
Gc plasmids
C. TANG
University of Oxford, Oxford (UNITED KINGDOM)
- 09:30-09:50 Phase-Variable LOS epitopes of Neisseria gonorrhoeae and their role in sex-specific epithelial adherence**
L.M.B. DE DEUS PONCES DE CARVALHO
University of Sheffield, School of Clinical Dentistry, Sheffield (UNITED KINGDOM)
- 09:50-10:10 Exploring the metabolism of Neisseria gonorrhoeae during infection through genome scale metabolic modelling**
D. CARRUTHERS-LAY
University of Toronto, Department of Molecular Genetics, Toronto (CANADA)
- 10:10-10:30 Interaction of human macrophages with Neisseria gonorrhoeae**
A.-M. DRAGOI
LSU Health Shreveport - Department of Molecular and Cellular Physiology, Shreveport (USA)
- 10.30-11.15 Coffee Break**
- Chairs: K. WALDRON, (POLONIA), M. REGAN (USA)
- 11:15-11:35 Gonococcal outer membrane vesicles induce porB-dependent epithelial cell mitophagy to enhance intracellular survival**
S. VAN DER VEEN
Department of Microbiology, School of Medicine, Zhejiang University, Hangzhou (CHINA)
- 11:35-11:55 Neisseria gonorrhoeae suppresses inflammation at the human cervix by spatially regulating the initial local cytokine responses**
W. SONG
University of Maryland, College Park - Department of Cell Biology and Molecular Genetics, College Park (USA)
- 11:55-12:15 The role of CD9 across the meningococcal infective pathway**
P. WOLVERSON
University of Sheffield, School of Clinical Dentistry, Sheffield (UNITED KINGDOM)

Program

3 APRIL

12:15-12:35 **Neisseria meningitidis Induces Dihydroceramide Accumulation and Alters Lipid Trafficking in Brain Endothelial Cells**

A. WEINMANN

*Julius-Maximilians-Universität Würzburg, Institute for Hygiene and Microbiology, Würzburg
(GERMANY)*

12:35-12:50 **POSTER AWARDS**

Program

3 APRIL

04/04/2025

10:00-13:00

Auditorium

Antimicrobial resistance: clinical relevance and how to address it

Chairs: B. BERÇOT (*FRANCE*), J. HICKS (*NEW ZEALAND*)

- 10:00-10:30** **Keynote Lecture**
Antimicrobial resistance in Neisseria gonorrhoeae globally: Clinical relevance and how to address it
M. Unemo
WHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro (SWEDEN)
- 10:30-10:50** **An Investigation of drug-drug interactions and resistance mutation interactions involving the Neisseria gonorrhoeae replisome**
B. BOWCUTT
Harvard University - Department of Immunology and Infectious Disease, Boston (USA)
- 10:50-11:10** **A novel solution for combating multi-drug resistance in Neisseria gonorrhoeae**
F. JEN
*Griffith University, Gold Coast (AUSTRALIA),
The Ohio State University, Ohio (USA)*
- 11:10-11:30** **Genome reorganization can contribute to antibiotic resistance in Neisseria gonorrhoeae**
D. STEIN
Univeristy of Maryland, College Park (USA)
- 11.30-12.00** **Coffee Break**
- Chairs: S. SAROJ (*INDIA*), M. P. MAHLANGU (*SOUTH AFRICA*)
- 12:00-12:20** **Vaccine potential of the Neisseria gonorrhoeae MafA 2/3 adhesin protein**
M. GIRGIS
Neisseria Research Group, Molecular Microbiology, School of Clinical and Experimental Sciences, Southampton (UNITED KINGDOM)
- 12:20-12:40** **Pharyngeal carriage study of UK adolescents reveals wide-spread carriage of genetically diverse Neisseria species harbouring various antimicrobial resistance mechanisms**
L. WALSH
Meningococcal Reference Unit, UK Health Security Agency, Manchester (UNITED KINGDOM)
- 12:40-13:00** **Antimicrobial resistance determinants associated with azithromycin resistance in South African Neisseria gonorrhoeae, 2017- 2021**
M.P. MAHLANGU
Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg (SOUTH AFRICA)
- 13:00-13:30** **CLOSING REMARKS**
C. AZZARI, M. PIZZA, R. RAPPUOLI

Program

4 APRIL

ANTIMICROBIAL RESISTANCE, THERAPEUTICS AND DIAGNOSTICS

- P001 Identifying a minimal set of mutations in penicillin-binding protein 2 from the ceftriaxone-resistant strain H041 that confer a majority of cephalosporin resistance**
BIVINS MARISSA
Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, USA
- P002 The GyrA-mediated in vivo fitness advantage in ciprofloxacin-resistant Neisseria gonorrhoeae is reproduced in media that mimics the thiamine- and iron-limited microenvironment of the genital tract**
LE VAN ADRIANA
Henry M. Jackson Foundation for the Advancement of Military Medicine, INC, Bethesda, USA
- FP004 The central role of the beta3-beta4 loop of penicillin-binding protein 2 in the cephalosporin resistance of N. gonorrhoeae**
DAVIES CHRISTOPHER
University of South Alabama, Mobile, USA
- FP005 Accelerated antimicrobial resistance testing of Neisseria gonorrhoeae in sexual health samples**
DHANJAL ANISHA
School of Clinical Dentistry, University of Sheffield, Sheffield, UNITED KINGDOM
- P006 Three cases of XDR ST16406 in Norway, 2024**
ELDHOLM VEGARD
Norwegian Institute of Public Health, Oslo, NORWAY
- P007 GonoGate: a modular vector assembly system for the expression of genes in Neisseria gonorrhoeae**
FLEMMING CHLOE
University of Waikato, Hamilton, NEW ZEALAND
- P008 Targeting cysteine biosynthesis for new antimicrobials**
HICKS JOANNA
University of Waikato, Hamilton, NEW ZEALAND
- P010 Artificial Intelligence-driven functional annotation and reverse vaccinology based approach to identify novel vaccine candidates against Neisseria gonorrhoeae**
KANT RAVI
Dr.B.R.Ambedkar Center for Biomedical Research, University of Delhi, New Delhi, INDIA
- P011 MOFs as novel antibacterial agents: a computational, material science and experimental investigation of their potential against Neisseria gonorrhoeae**
KANT RAVI
Dr.B.R.Ambedkar Center for Biomedical Research, University of Delhi, New Delhi, INDIA
- P012 Phenotypic and genomic characterization of multi-drug resistant gonococcal isolates from the global surveillance GEIS antimicrobial resistance program**
LE VAN ADRIANA
Henry M. Jackson Foundation for the Advancement of Military Medicine, INC, Bethesda, USA

Program

POSTERS

- P013 In vitro activity of an aqueous allicin extract against Neisseria gonorrhoea**
MAHARJAN SUNIL
Medicines And Healthcare Products Regulatory Agency, Potters Bar, UNITED KINGDOM
- P014 Combatting antibiotic resistance in Neisseria gonorrhoeae by targeting CysK, the final enzyme in cysteine biosynthesis**
MCGARVIE JACK
School of Science, University of Waikato, Hamilton, NEW ZEALAND
- P015 Active-site tyrosine-422 is crucial for acylation and transpeptidation in penicillin-binding protein 2 from multi-drug resistant Neisseria gonorrhoeae H041**
MONTEIRO-PAI JUANITA
University of South Alabama, Mobile, USA
- FP016 Impact of the L421P mutation in the ponA1 gene, encoding Penicillin-Binding Protein 1, on fitness and antibiotic resistance in Neisseria gonorrhoeae**
NICHOLAS ROBERT
University of North Carolina at Chapel Hill, Chapel Hill, USA
- P017 In vivo-selected gentamicin-resistant Neisseria gonorrhoeae exhibits a fitness cost in vitro and in vivo, and compensatory mutations may support spread of resistance**
LE VAN ADRIANA
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, USA
- P018 RNase HI as a drug target in Neisseria gonorrhoeae**
PENNYCUICK KATE
School of Biological Sciences, University of Auckland, Auckland, NEW ZEALAND
- P020 Identification of two expanded-spectrum cephalosporins that target penicillin-binding protein 1 (PBP1) in Neisseria gonorrhoeae**
ROBERT A NICHOLAS
University of North Carolina at Chapel Hill, Chapel Hill, USA
- P021 Re-evaluating the potential impact of doxycycline post-exposure prophylaxis (Doxy-PEP) on the selection of resistance in Neisseria commensals**
ROBINSON LEAH
Rochester Institute of Technology - College of Science, Rochester, USA
- P022 High reliability and specificity of agglutination tests in the laboratory diagnosis of bacterial meningitis at the subnational level in Togo, from 2016 to 2024**
SADJI ADODO YAO
National Institute of Hygiene, Lome, Togo
- P025 Botanical extract-guided discovery of phenethyl caffeate as antimicrobial compound with in vitro and in vivo anti-gonococcal activity through inhibition of elongation factor Tu**
VAN DER VEEN STIJN
Department of Microbiology, School of Medicine, Zhejiang University, Hangzhou, CHINA

Program

POSTERS

BACTERIAL PHYSIOLOGY AND VIRULENCE, AND IN VIVO & IN VITRO MODELS

- P026 Biochemical studies of Type IV pilus tip-located proteins of Neisseria gonorrhoeae support a licensing model for fiber initiation**
APPLEGATE JUSTIN
University of Washington, Seattle, USA
- P027 Decoding bacterial epigenetic regulation via phase-variable methyltransferases in pathogenic Neisseria species**
ASCARI ALICE
Institute for Biomedicine and Glycomics, Griffith University, Gold Coast, AUSTRALIA
- P028 Rigidity dependent growth of Neisseria microcolonies**
BIAIS NICOLAS
Laboratoire Jean Perrin - Sorbonne Université, Paris, FRANCE
- P029 Selection of a hyper adhesive meningococcal population by a filamentous phage**
BILLE EMMANUELLE
Université Paris Cité, INSERM U1151, CNRS UMR8253, Institut Necker-Enfants Malades, Paris, FRANCE
- P031 Contributions of C4b-binding protein to interactions of Neisseria gonorrhoeae and primary human neutrophils**
BRODEN MARY
University of Virginia, Charlottesville, USA
- P032 Genotypic and phenotypic studies of gonococcal strains of different origins (Sexually Transmitted Infections, invasive infections and colonisations): focus on serum resistance**
BROUSSEAU JULIE
Institut Necker-Enfants Malades, INSERM U1151, CNRS UMR 8253, Paris, FRANCE
- P033 Neisseria gonorrhoeae infection in the genital tract alters the murine gut microbiome**
CHIEU RYAN
University of Toronto, Department of Molecular Genetics, Toronto, CANADA
- P034 Impact of intergenic region variation on gene expression among phylogenetically-related Neisseria meningitidis Isolates**
CLARK JACK
University of Leicester - Department of Genetics, Genomics and Cancer Sciences, Leicester, UNITED KINGDOM
- P035 Complement C5b-C8 and C5b-C9 membrane attack complexes potentiate antimicrobial activity against drug-resistant Neisseria gonorrhoeae**
CRISS ALISON
University of Virginia- Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, USA
- P036 Investigating the SLAM translocon throughout the Neisseria**
CURRAN DAVID
University of Toronto, Toronto, CANADA

Program

POSTERS

- FP037 Female sex hormones enhance gonococcal colonization at the endocervix by modifying cervical mucus**
DI BENIGNO SOFIA
University of Maryland, College Park - Department of Cell Biology and Molecular Genetics, College Park, USA
- P038 Neisseria gonorrhoeae adaptation during vaginal colonization of CEACAM-humanized mice**
DYZENHAUS SOPHIE
University of Toronto, Toronto, CANADA
- P039 Pharyngeal colonization by Neisseria gonorrhoeae in humanized transgenic mice**
FEGAN JAMIE
Department of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, CANADA
- P040 Ribosomal protein paralogs and zinc homeostasis in Neisseria gonorrhoeae**
FOREHAND AMY
University of Virginia, Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, VA, USA
- P041 Gene co-expression between Neisseria gonorrhoeae and the genital tract microbiome during natural mucosal infection**
GENCO CAROLINE
Tufts University School of Medicine, Boston, USA
- P042 Dynamism of the CD9 interactome during meningococcal infection**
GREEN LUKE
School of Clinical Dentistry, University of Sheffield, Sheffield, UNITED KINGDOM
- P044 Screening fatty acids as antimicrobial agents for treating oral gonorrhoea using a validated 2D human oral cell model**
HAMZA SYED AMEER
Melbourne Dental School, The University of Melbourne, Melbourne, AUSTRALIA
- FP045 Macrophage infectivity potentiators are important in pathogenic Neisseria spp. for host innate defences and antibiotic resistance.**
HOOTON THITIWAT JOE
University of Western Australia - Marshall Centre for Infectious Disease Research and Training, Perth, AUSTRALIA
- P046 A two-component monooxygenase reductase component, HpaC sensitizes Neisseria gonorrhoeae to an iron-dependent antibiotic streptonigrin**
HU LINDA
Northwestern University Feinberg School of Medicine, Chicago, USA
- P047 Infection of cornea models with different Neisseria gonorrhoeae derivatives to study the importance of the Type IV pilus for bacterial adherence and infection outcome**
KAFURI CIFUENTES LINA MARIA
Julius-Maximilians Universität Würzburg, Würzburg, GERMANY
- P048 Environmental desiccation induces VBNC state in Neisseria meningitidis**
KANOJIYA POONAM
Symbiosis International (Deemed University), Pune, INDIA

Program

POSTERS

- P049 High throughput testing for associations between phase variation states and disease-associated phenotypic traits of meningococcal disease and carriage isolates**
KIMANI MERCY
University of Leicester, Leicester, UNITED KINGDOM
- P050 Unraveling the role of LutACB operon for the survival of Neisseria gonorrhoeae in the presence of neutrophils**
KOZJAK-PAVLOVIC VERA
Department of Microbiology, University of Wuerzburg, Wuerzburg, GERMANY
- P052 Genetic analyses of PilC function in Neisseria gonorrhoeae type 4 pili support a licensing model for fiber initiation**
LITT ZOEY
University of Washington, Seattle, USA
- P053 The periplasmic zinc binding protein Ngo1049 aids Neisseria gonorrhoeae assimilation to zinc limitation**
LIYAYI IAN
University of Virginia, Charlottesville, USA
- P055 The gonococcal candidate vaccine antigen NGO1701 is a periplasmic copper-binding protein, Csp1**
MASSARI PAOLA
Tufts University School of Medicine, Department of Immunology, Boston, USA
- P056 Lipooligosaccharide (LOS) of contemporary disseminated gonococcal (DGI) strains**
MCLAUGHLIN STEPHANIE
University of Washington, Seattle, USA
- P057 Investigating a putative surface lipoprotein assembly modulator and dependent cargo in Neisseria muscoli**
MCVICKER SLOANE
University of Arizona - Department of Immunobiology, Tucson, USA
- P058 Advanced human UV mucosal infection models as validation tools for vaccine development**
MEHLING HELENE
Department of Microbiology, Biozentrum am Hubland, University of Wuerzburg, Wuerzburg, GERMANY
- FP059 Initiation of gonococcal pilus assembly by PilC: the licensing model**
MERZ ALEXEY
University of Washington, Seattle, USA
- P060 Using CRISPRi to modulate Neisseria gonorrhoeae pilin antigenic variation**
METAANE SELMA
Northwestern University, Chicago, USA
- P061 Restriction-methylation systems in Neisseria gonorrhoeae pilin antigenic variation**
METAANE SELMA
Northwestern University, Chicago, USA

Program

POSTERS

- P062 Regulatory mechanisms of *Neisseria subflava* capsule polysaccharide biosynthesis**
NGUYEN ANH
University of Arizona - Department of Immunobiology, Tucson, USA
- P063 The *Neisseria meningitidis* capsule plays a crucial role in impairing efflux transporter function in brain endothelial cells**
NOSRATABADI FATEMEH
Institute for Hygiene and Microbiology, University of Würzburg, Würzburg, GERMANY
- P064 Innate Immune responses to *Neisseria gonorrhoeae* in a female mouse model of ascending reproductive tract infection**
ANN JERSE
Uniformed Services University of the Health Sciences, Bethesda, USA
- P065 *Lactobacillus crispatus* enters epithelial cells via caveolae-mediated endocytosis and increases internalization of *Neisseria meningitidis* but prevents transcytosis**
PILHEDEN SARAH
Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, SWEDEN
- P066 Novel approach to selecting a contemporary *Neisseria gonorrhoeae* strain for oropharyngeal gonorrhoea human challenge: a genomics-based analysis**
POLLOCK GEORGINA
Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, AUSTRALIA
- P067 Investigating the contribution of *Neisseria gonorrhoeae* lactate metabolism to oxidative stress resistance**
POTTER AIMEE
University of Iowa - Dept of Microbiology and Immunology, Iowa City, USA
- P068 Investigation of metal uptake systems in commensal *Neisseria subflava***
RENDON MARIA
Immunobiology Department and BIO5 Institute, University of Arizona, Tucson AZ. USA
- P070 Gene conversion of the gonococcal NEIS1446-NEIS1442 operon contributes to anaerobic survival of the *Neisseria meningitidis* urethritis clade, NmUC**
RODRIGUEZ EMILIO
Emory University - Department of Medicine, Atlanta, USA
- P071 Meningococcal capsule in determining the initial outcome of host-pathogen interactions**
SAROJ SUNIL
Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Pune, INDIA
- P072 Characterisation and development of gonococcal glycan-binding proteins as therapeutic targets**
SEMCHENKO EVGENY
Griffith University, Gold Coast, AUSTRALIA
- P073 Evolution of the Neisseriaceae family**
FREDERIC VEYRIER
INRS-Centre Armand-Frappier Santé Biotechnologie, Bacterial Symbionts Evolution, Laval, CANADA

Program

POSTERS

- P074 The role of acetyl-phosphate in the pathogenesis of *Neisseria gonorrhoeae***
SHAW JONATHAN
School of Medicine and Population Health, University of Sheffield, Sheffield, UNITED KINGDOM
- P075 Phase-variable expression of gonococcal Igta and its impact on the LOS structure**
SPINSANTI MARCO
GSK, Siena, ITALY
- P076 Identification of an interaction between the C-lobe of TbpB and the C-lobe of human transferrin: a potential role in the removal of iron-stripped transferrin from the TbpA, TbpB, transferrin complex**
STOUDENMIRE JULIE
Georgia State University, Atlanta, USA
- P077 Abdominal presentation of invasive meningococcal disease is correlated with the induction of plasminogen activator inhibitor in adipocyte of the omentum**
TAHA MUHAMED-KHEIR
Institut Pasteur, Paris, FRANCE
- P078 Sulfur assimilation and metabolism in *Neisseria gonorrhoeae***
VAN NIEKERK STACY
Te Huataki Waioara, School of Health, University of Waikato, Hamilton, NEW ZEALAND
- FP079 Evolution and phylogeny of the newly characterized Ssn protein family of site-specific single-stranded DNA endonucleases in Neisseriaceae and beyond**
VEYRIER FRÉDÉRIC
Armand-Frappier Santé Biotechnologie Research Centre, INRS, Laval, CANADA
- P080 Isolation of typically commensal, occasionally pathogenic *Neisseria* from clinical samples**
WALSH LLOYD
Meningococcal Reference Unit, UK Health Security Agency, Manchester, UNITED KINGDOM
- FP081 Neutrophil-derived catecholamines support gonococcal resistance to nutritional immunity**
WESTLAKE CAMILLE
University of Virginia - Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, USA
- FP082 Extracellular vesicles carrying complement inhibitors enhance *Neisseria gonorrhoeae* serum resistance**
WEYAND NATHAN
Ohio University, Athens Oh, USA

Program

POSTERS

CLINICAL STUDIES AND TRANSLATIONAL RESEARCH AND CORRELATES OF PROTECTION

- FP083 Clinical management of gonorrhoea contacts: evaluation of a change from universal to selective treatment**
CHOW ERIC
Melbourne Sexual Health Centre, Alfred Health, Melbourne, AUSTRALIA
- FP085 A Bioluminescence-based high-throughput serum bactericidal assay to detect bactericidal antibodies against n. meningitis in human sera**
FANTONI GIULIA
University of Siena, Siena, ITALY
- FP086 Two decades of Neisseria gonorrhoeae evolution in Western Kenya**
HARRISON ODILE
University of Oxford, Nuffield Department of Population health, Oxford, UNITED KINGDOM
- P087 Exploring community and expert perceptions of the acceptability of an oropharyngeal gonorrhoea controlled human infection model in Australia**
MCCARTHY JAMES S.
Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, AUSTRALIA
- P088 Design of a phage immunoprecipitation sequencing panel to capture the human antibody repertoire against Neisseria gonorrhoeae**
NEUBAUER VICKERS ERIC
Harvard University - Department of Infectious Diseases, Boston, USA
- FP090 Evaluation of the impact of insecurity and the COVID-19 pandemic on meningitis surveillance in Burkina Faso, 2015–2021**
SAWADOGO ABDOUL -GUANIYI
Jhpiego Corporation, Ouagadougou, BURKINA FASO

Program

POSTERS

MENINGOCOCCAL AND GONOCOCCAL VACCINES

- FP091 Turbo, an adjuvant for multivalent meningococcal glycoconjugate vaccines**
ALUGUPALLI KISHORE
TurboVax Inc, Philadelphia, USA
- P092 Profiling of the serological response to gonococcus in healthy subjects receiving 4CmenB vaccine**
ANCARANI LUDOVICA
GSK Vaccines, Siena, ITALY
- P093 Fine tuning the neutralizing antibody response through rational design of a nutrient acquisition protein**
AU YUEN TUNG NATALI
University of Toronto, Department of Biochemistry, Toronto, CANADA
- P094 Immunogenicity following MenB-FHbp vaccination among university students in the US**
BASTA NICOLE
McGill University, School of Population and Global Health, Department of Epidemiology and Biostatistics, Montreal, QC, CANADA
- P096 Status of the rollout of the meningococcal serogroup A conjugate vaccine in African meningitis belt countries in 2023**
BITA FOU DA ANDRE ARSENE
Andre Arsene Bit a Fouda, Brazzaville, REPUBLIC OF THE CONGO
- P097 Reactive vaccination with the new multivalent meningococcal conjugate vaccine responding to meningitis epidemics in Nigeria and Niger in 2024**
BITA FOU DA ANDRE ARSENE
World health Organization, African Region, Brazzaville, REPUBLIC OF THE CONGO
- P098 Impact of meningitis epidemic response in the African meningitis belt from 2011 to 2023**
BITA FOU DA ANDRE ARSENE
World Health Organization, Brazzaville, REPUBLIC OF THE CONGO
- P099 Characterization of different N. gonorrhoeae OMV preparations to investigate 4CMenB cross protection against gonococcus**
BUFFI GIADA
Gsk Vaccines, Siena, ITALY
- P100 Updated impact of the UK MenACWY adolescent vaccination programme on carriage four years after implementation**
CARR JEREMY
University of Oxford, Oxford, UNITED KINGDOM
- P101 Development of an assay for quantifying lipooligosaccharide in Neisseria gonorrhoeae native outer membrane vesicles**
DISSANAYAKE SENURI NAYANIKA
Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UNITED KINGDOM

Program

POSTERS

- P102 4CMenB meningococcal vaccine induced antibody profile and function against Neisseria gonorrhoeae over 24 months post vaccination**
ESKANDARI SHARAREH
Institute for Biomedicine and Glycomics, Griffith University, Gold Coast, AUSTRALIA
- P103 Robust Neisseria meningitidis serogroup B breadth of coverage against 144 disease isolates following two doses of a MenB-fHbp-containing vaccine**
FINDLOW JAMIE
Vaccines/Antivirals and Evidence Generation, Pfizer Ltd, Surrey, Kent, UNITED KINGDOM
- FP104 A combination native outer membrane vesicle (NOMV) vaccine to prevent meningococcal and gonococcal disease**
GIUNTINI SERENA
Omvax Inc., Oakland, California, USA
- P106 Phase 2/3 study of the EuBiologics pentavalent meningococcal ACWYX conjugate vaccine compared to MENVEO® or Nimenrix® in healthy children through adults in Mali and The Gambia**
HAIDARA FADIMA CHEICK
Centre pour le Développement des Vaccins - Mali, Bamako, MALI
- P107 Persistence of immune responses to pentavalent (ACYWX) meningococcal conjugate vaccine in young Malian children**
MARTELLET LIONEL
Center for Vaccine Innovation and Access, PATH, Seattle, Washington, USA
- P108 First in human clinical trial: promising result for a pentavalent meningococcal conjugate vaccine; EuNmCV-5: Safety and immunogenicity, randomized, active-controlled in the Republic of Korea**
HER HOWARD
EuBiologics Co., LTD, Seoul, SOUTH KOREA
- P109 Use of 4CMenB (Bexsero®) vaccination as an outbreak control measure in a care home for the elderly following two cases of MenB Invasive meningococcal disease**
HEYMER EMMA
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, Colindale, London, UNITED KINGDOM
- P110 Outer membrane vesicles of Neisseria meningitidis used as adjuvant for recombinant protein induce an immune response to meningococci and gonococci strains**
IZELI PORTILHO AMANDA
Adolfo Lutz Institute, Immunology Center, São Paulo, BRAZIL
- FP112 Insights into the epitope-specific roles of Neisseria gonorrhoeae reduction modifiable protein (Rmp) in modulating bactericidal activity**
KASIMOV VASILLI
Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD, AUSTRALIA
- P113 Meningococcal vaccines for high-risk populations: potential role of MenABCWY vaccine**
KAVALIAUSKAITE JUSTINA
GSK, Brussels, Belgium

Program

POSTERS

- P114 Evaluating the bi-partite transferrin/ lactoferrin binding proteins as vaccine targets against pathogenic Neisseria species**
KHAW KEN YU
University of Calgary, Calgary, CANADA
- P115 Understanding the immunity gap due to national lockdown during the Covid-19 pandemic for meningococcal disease**
LOUTH JENNIFER
UKHSA Vaccine Evaluation Unit, Manchester, UNITED KINGDOM
- P116 Willingness of undergraduate students to take up gonococcal vaccines and factors influencing their decision in Ebonyi state south-east Nigeria**
MADUBUEZE UGOCHUKWU
Alex-Ekwueme Federal University Teaching Hospital Abakaliki, Abakaliki, Ebonyi State, NIGERIA
- P118 NEIS CRE: centre of research excellence in Neisseria disease control**
MARSHALL HELEN
Womens and Childrens Health Network and The University of Adelaide, Adelaide, AUSTRALIA
- P119 Immunological characterization of novel gonococcal hypothetical protein vaccine candidates**
MASSARI PAOLA
Tufts University School of Medicine, Department of Immunology, Boston, USA
- P120 Method acting: how varied isolation methods impact antigen-specific responses to outer membrane vesicle vaccines**
ANN JERSE
Uniformed Services University of the Health Sciences, Bethesda, USA
- P121 Can meningitis be eliminated in Ghana? Insights from a stochastic model considering the possibility of re-introduction**
OWUSU MARK ASARE
Department of Veterinary Medicine, University of Cambridge, Cambridge, UNITED KINGDOM
- P122 Engineering ovalbumin-tagged antigens and single chain MHC-II molecules as tools to investigate humoral and cellular immune responses**
PALINSKI JAKUB
University of Manchester, Faculty of Biology, Medicine and Health, Manchester, UNITED KINGDOM
- P123 4CMenB coverage assessment in South Africa (2016-2023): genomics and functional pairing**
PRINCIPATO SILVIA
GSK Vaccines, Siena, ITALY
- P124 Development of an antigenicity ELISA for analysis of potency of gonovac**
QUINN MOLLY
Jenner Institute, Oxford, UNITED KINGDOM
- P125 Intrinsic bactericidal activity against a diverse panel of invasive isolates following meningococcal B vaccination in university students**
BASTA NICOLE
Mcgill University, Montréal-Québec (CANADA)

Program

POSTERS

- P126** **Analysis of Neisseria meningitidis serogroup B isolates and factor H-binding protein expression in Canada: data from the Canadian immunization monitoring program active (IMPACT), 2013-2020**
SADARANGANI MANISH
Department of Pediatrics - University of British Columbia, Vancouver, CANADA
- P127** **Impact of the administration of antimeningococcal vaccines (ACWY) on the microbiological profile of bacterial meningitis in Togo, 2016 to 2024**
SADJI ADODO YAO
National Institute of Hygiene, Lome, TOGO
- P130** **Evaluating the potential impact of a gonococcal vaccine on gonorrhoea in a remote Australian Indigenous setting: a mathematical modelling study**
SEIB KATE
Institute for Biomedicine and Glycomics, Gold Coast, AUSTRALIA
- P131** **Controlled temperature chain (CTC) studies of MenFive vaccine, the world's first WHO pre-qualified pentavalent meningococcal ACYWXX conjugate vaccine**
SHARMA PANKAJ
Serum Institute of India Pvt. Ltd., Pune, India, Quality Control, Pune, INDIA
- P132** **Immune responses in vaginal secretions and sera from retro-orbital and saphenous blood sampling sites in mice immunized intranasally with experimental ACP/MtrE gonococcal vaccines**
SIKORA ALEKSANDRA
Oregon State University, Corvallis, USA
- P133** **Cholera toxin subunit B and outer membrane proteins of Neisseria meningitidis: evaluation of the immunogenicity in elderly mice**
SIMÕES DE MELO NICOLY
Adolfo Lutz Institute, Immunology Center, São Paulo, BRAZIL
- FP134** **The importance of selecting outer membrane antigens from Neisseria meningitidis strains associated with different meningococcal polysaccharides for an effective protection**
SIMÕES DE MELO NICOLY
Adolfo Lutz Institute, Immunology Center, São Paulo, BRAZIL
- P135** **Cross-reactive antibody responses and glycosylation profiles induced by 4CMenB vaccination against Neisseria gonorrhoeae**
SLESARENKO VALENTIN
Institute for Biomedicine and Glycomics, Griffith University, Gold Coast, AUSTRALIA
- P136** **Evaluation of the MenAfrivac vaccination strategy implementation in the Boké region in 2023**
SOW YAYÉ HAWA
Expanded Program of Immunisation, Conakry, GUINEA REPUBLIC
- FP137** **Validation of bacterial meningitis case-based data in Niger, from 2021 to 2023: Analysis of validated data contribution to assess the impact of the new multivalent meningococcal conjugate vaccine**
TARBANGDO TIGA FELIX
Davycas International, Ouagadougou, BURKINA FASO

Program

POSTERS

- P138 Characterization of a gonococcal 37kDa protein that is potentially the protective antigen target in 4CMenB**
THOMAS CYNTHIA THOMAS
Department of Microbiology and Immunology, University of North Carolina- Chapel Hill, Chapel Hill, USA
- P139 Development of functional antibody assays for evaluation of Neisseria gonorrhoeae vaccine candidates using human and mouse immunized sera.**
THOMAS KEENA
University of Virginia - Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, USA
- P141 Anti-gonococcal cross-reactive antibodies induced by immunization with 4CMenB activate CD16/CD32 and induce NK cell cytokine production**
ZHU WEIYAN
Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, USA
- P142 Extending Pentavalent MenABCWY meningococcal vaccine dosing intervals is safe and induces comparable or greater hSBA responses in healthy adolescents**
ZOLOTAS LEFTERIS
Pfizer Vaccine R&D UK Ltd, Marlow, UNITED KINGDOM

Program

POSTERS

NEISSERIAE: CLINICAL RELEVANCE AND EPIDEMIOLOGY IN 2025

- P143** **Genome epidemiological analysis of Neisseria gonorrhoeae in Norway 2016-2023 indicate changing epidemiology in the wake of the COVID-19 pandemic**
ALFSNES KRISTIAN
Division for Infection Control, Norwegian Institute of Public Health, Oslo, NORWAY
- P144** **Enhancing meningitis response in Sub-Saharan Africa: an evaluation of the meningitis early warning system (MEWS)**
BERRY ISHA
Infectious Diseases Programs, CDC Foundation, Atlanta, USA
- FP145** **Update on the epidemiology of invasive meningococcal disease: Canada 2002-2023**
BETTINGER JULIE
Vaccine Evaluation Center British Columbia Childrens Hospital Research Institute UBC, Vancouver, CANADA
- P146** **Associations between environmental factors and epidemic meningitis risk across Africa**
CLIFF MOLLY
Disease Dynamics Unit, Dept. of Veterinary Medicine, University of Cambridge, Cambridge, UNITED KINGDOM
- P147** **Characteristics of invasive meningococcal disease (IMD) cases in Taiwan between 1996-2020**
COSTE FLORENCE
Sanofi, Lyon, FRANCE
- P148** **ST-2196 prevalence in the province of Chaco, Argentina, 2017-2022**
EFRON ADRIANA MÓNICA
Servicio Bacteriología Clínica, Laboratorio Nacional de Referencia de Meningococo. Instituto Nacional de Enfermedades In, Buenos Aires, ARGENTINA
- P149** **Outbreak of N. meningitidis B ST-162 cc in the City of Rosario, Province of Santa Fe, Argentina, from May to October 2024**
EFRON ADRIANA MÓNICA
Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbraán, Departamento Bacteriología, Buenos Aires, ARGENTINA
- P150** **Molecular characterization and phylogenetic analysis of Neisseria meningitidis Isolates in Ismailia Province, Egypt 2020-2024**
FAWZY MOHAMED
Faculty of Veterinary Medicine, Suez Canal University, Department of Virology and Immunology, Ismailia, EGYPT
- P151** **Meningococcal carriage and transmission dynamics in college students**
FINDLOW JAMIE
Global Scientific Affairs, Meningococcal Vaccines, Vaccines/Antivirals & Evidence Generation, Pfizer Ltd, Surrey, UNITED KINGDOM
- FP152** **Assessing the use of point of care diagnostic testing for invasive meningococcal disease and the impact of this on the implementation of essential public health actions**
HEYMER EMMA
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, Colindale, London, UNITED KINGDOM

Program

POSTERS

- FP153 Assessing maternal contributions to the prevention and control of sporadic meningitis in rural communities: a growing concern of geographic risk dynamics and migration from high-burden regions**
IWU CHINEDU ANTHONY
Imo State University/Teaching Hospital, Owerri, NIGERIA
- P154 An improved core genome MLST scheme for Neisseria meningitidis**
JOLLEY KEITH
University of Oxford, Department of Biology, Oxford, UNITED KINGDOM
- P155 Impacts of the COVID-19 outbreak on gonorrhoea prevalence among high-risk behavior group of men in Rajshahi city of Bangladesh**
KALAM MOHAMMED ABUL
Quick Health Service Centre (QHSC), Rajshahi, BANGLADESH
- FP156 High Neisseria meningitidis oropharyngeal carriage trends in men who have sex with men: a public health warning**
MEMON AMINAH
University of Oxford, Nuffield Department of Population Health, Oxford, UNITED KINGDOM
- P157 Assessing the awareness and risks of contracting meningococcal meningitis among university students in northern Ghana.**
MUSAH SUALAH HARIS
University for Development Studies, Tamale, GHANA
- P158 Advances in cataloguing bacterial population structure: development of a life identification number (LIN) barcoding system for Neisseria meningitidis.**
PARFITT KASIA
University of Oxford, Department of Biology, Oxford, UNITED KINGDOM
- P159 Analysing life identification number codes to understand the effect of vaccine strategies on Neisseria meningitidis population structure**
PARFITT KASIA
University of Oxford - Department of Biology, Oxford, UNITED KINGDOM
- P160 Ten-year retrospective review of medical records at five hospitals in the United States highlights the potential for under-detection of invasive meningococcal disease**
ANGULO FREDERICK
Norton Health Care, Louisville, USA
- P161 Burden and clinical characteristics of invasive meningococcal disease in Canada between 2012-2023: data from the Canadian immunization monitoring program active (IMPACT)**
SADARANGANI MANISH
Department of Pediatrics - University of British Columbia, Vancouver, CANADA

Program

POSTERS

- P163** **Trend, pattern, and laboratory outcome of meningitis cases in Jigawa State Northwestern, Nigeria: A 10-year review of case-based surveillance data**
SHEHU USMAN LAWAL
Department of Community Medicine, Bayero University/Aminu Kano Teaching Hospital, Kano, NIGERIA
- P164** **Genomics of oropharyngeal meningococcal carriage isolates in an urban STD clinic**
TZENG YIH-LING
Emory University School of Medicine, Atlanta, USA
- P165** **Comparison of phase variable genes in persistent carriage and disease-causing isolates of *Neisseria meningitidis* serogroup W.**
WEBSTER DEVEN
Department of Genetics, Genomics and Cancer Sciences, University of Leicester, Leicester, UNITED KINGDOM

Program

POSTERS

POLICY AND COST-EFFECTIVENESS

FP166 Identification and control of an outbreak of serogroup Y invasive meningococcal disease in Quebec

DE WALS PHILIPPE

Laval University, Québec, CANADA

FP168 Estimating the impact of immunization against Neisseria meningitides with a pentavalent conjugate vaccine compared to monovalent serogroup A conjugate vaccine in the African meningitis belt

HABIB ABDULRAZAQ

Bayero University Kano, Kano, NIGERIA

Program

POSTERS

SPONSORS ACKNOWLEDGMENT

